Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Tyler (TYL) Takes Over Financial Cloud Software Provider VendEngine

Published 06/06/2021, 09:20 PM
Updated 07/09/2023, 06:31 AM

Continuing with its strategy of growing through acquisitions, Tyler Technologies (NYSE:TYL) TYL last week announced entering into a definitive agreement to buy VendEngine for approximately $84 million in cash. The transaction is anticipated to complete during the third quarter of this calendar year.

Operating in more than 230 counties and 32 states, VendEngine is a privately-held company that focuses on providing cloud-based software to be used in correctional facilities. The company offers financial management applications and communication platforms that are used by inmates of jails and prisons.

Its services include a website, JailFunds.com, through which families of jail inmates deposit money to be spent on making phone calls and buying items from prison commissaries. It also provides video visitation, in-bound e-mails and texts, medical requests, access to education, certificates and legal research resources, services to the prisoners.

Therefore, the acquisition of VendEngine will further expand Tyler’s correctional facilities portfolio.

Acquisitions Fueling Growth

Tyler’s growth trajectory, in recent years, has been riding on acquisitions. This April, the company completed the proposed acquisition of NIC (NASDAQ:EGOV) Inc. to bank on the pandemic-induced shift to online services and electronic payments by governments. This buyout is anticipated to be accretive to Tyler’s non-GAAP earnings, EBITDA, recurring revenue mix and free cash flow per share in 2021.

In the same month, Tyler purchased cloud-based school scheduling platform, ReadySub, to expand and strengthen its school portfolio. The transaction will help the company bring in more comprehensive schooling solutions to its school district clients, by helping them implement all-in-one workflows.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In late March, the company announced the acquisition of DataSpec, a veterans’ claim management software firm, for an undisclosed amount. The acquisition will help Tyler enhance its capabilities and strengthen the firm’s position in the veterans’ benefits management solutions market.

Tyler has a solid balance sheet with ample liquidity position and fewer debt obligations that provide it the flexibility to pursue growth initiatives, including acquisitions. As of Mar 31, 2021, cash and cash equivalents were $1.25billion. Further, the company had generated free and operating cash flows of $61.7 million and $71.7 million, respectively. Markedly, the firm has been able to regularly increase its cash flow from operations in the last five years.

Tyler is likely to pursue more acquisitions that will strategically align with its current offerings. Along with investments in research & development (R&D), acquisitions are likely to strengthen the firm’s product offerings and clientele over the long run.

Zacks Rank & Stocks to Consider

Tyler currently carries a Zacks Rank #4 (Sell).

Better-ranked stocks in the broader technology sector include Lam Research Corporation (NASDAQ:LRCX) LRCX, ASML Holding (NASDAQ:ASML) N.V. ASML and Facebook (NASDAQ:FB) FB, all sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

The long-term earnings growth rate for Lam Research, ASML Holding, and Facebook is currently pegged at 32.8%, 29.8% and 20.1%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASML Holding N.V. (ASML): Free Stock Analysis Report

Lam Research Corporation (LRCX): Free Stock Analysis Report

Facebook, Inc. (FB): Free Stock Analysis Report

Tyler Technologies, Inc. (TYL): Free Stock Analysis Report

To read this article on Zacks.com click here.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.